{
    "Clinical Trial ID": "NCT00077857",
    "Intervention": [
        "INTERVENTION 1: ",
        "  1250 mg/m^2 Capecitabine + Docetaxel",
        "  1250 mg/m^2 capecitabine (Xeloda\u00ae) orally twice a day on days 1 to 14 of each 3 week cycle, in combination with docetaxel (Taxotere\u00ae) 75 mg/m^2 intravenous on day 1 of each 3 week cycle.",
        "INTERVENTION 2: ",
        "  825 mg/m^2 Capecitabine + Docetaxel",
        "  825 mg/m^2 capecitabine orally twice a day on days 1 to 14 of each 3 week cycle, in combination with docetaxel 75 mg/m^2 intravenous on day 1 of each 3 week cycle."
    ],
    "Eligibility": [
        "Inclusion Criteria:",
        "  women >=18 years of age;",
        "  >=1 target lesion;",
        "  locally advanced or metastatic breast cancer;",
        "  demonstrated resistance to anthracycline;",
        "  >=2 regimens of chemotherapy for advanced/metastatic disease.",
        "Exclusion Criteria:",
        "  previous treatment with Xeloda, continuous 5-fluorouracil infusion, or other oral fluoropyrimidines;",
        "  previous treatment with paclitaxel or docetaxel for advanced/metastatic disease."
    ],
    "Results": [
        "Outcome Measurement: ",
        "  Time to Progression of Disease or Death",
        "  Progression Free Survival was defined as the time from the date of randomization to the day of documented disease progression or death due to any cause.",
        "  Time frame: Event driven (after 350 events). Median observation time was approximately 16 months.",
        "Results 1: ",
        "  Arm/Group Title: 1250 mg/m^2 Capecitabine + Docetaxel",
        "  Arm/Group Description: 1250 mg/m^2 capecitabine (Xeloda  ) orally twice a day on days 1 to 14 of each 3 week cycle, in combination with docetaxel (Taxotere  ) 75 mg/m^2 intravenous on day 1 of each 3 week cycle.",
        "  Overall Number of Participants Analyzed: 230",
        "  Median (95% Confidence Interval)",
        "  Unit of Measure: Months  7.9        (6.9 to 8.5)",
        "Results 2: ",
        "  Arm/Group Title: 825 mg/m^2 Capecitabine + Docetaxel",
        "  Arm/Group Description: 825 mg/m^2 capecitabine orally twice a day on days 1 to 14 of each 3 week cycle, in combination with docetaxel 75 mg/m^2 intravenous on day 1 of each 3 week cycle.",
        "  Overall Number of Participants Analyzed: 229",
        "  Median (95% Confidence Interval)",
        "  Unit of Measure: Months  5.8        (4.9 to 7.1)"
    ],
    "Adverse Events": [
        "Adverse Events 1:",
        "  Total: 41/217 (18.89%)",
        "  Febrile neutropenia 13/217 (5.99%)",
        "  Neutropenia 6/217 (2.76%)",
        "  Leukopenia 2/217 (0.92%)",
        "  Anaemia 0/217 (0.00%)",
        "  Atrial flutter 0/217 (0.00%)",
        "  Cardiac failure 0/217 (0.00%)",
        "  Cardiogenic shock 1/217 (0.46%)",
        "  Cardiopulmonary failure 0/217 (0.00%)",
        "  Stomatitis all 5/217 (2.30%)",
        "  Diarrhoea 2/217 (0.92%)",
        "  Vomiting 2/217 (0.92%)",
        "Adverse Events 2:",
        "  Total: 53/248 (21.37%)",
        "  Febrile neutropenia 14/248 (5.65%)",
        "  Neutropenia 4/248 (1.61%)",
        "  Leukopenia 0/248 (0.00%)",
        "  Anaemia 1/248 (0.40%)",
        "  Atrial flutter 1/248 (0.40%)",
        "  Cardiac failure 1/248 (0.40%)",
        "  Cardiogenic shock 0/248 (0.00%)",
        "  Cardiopulmonary failure 1/248 (0.40%)",
        "  Stomatitis all 0/248 (0.00%)",
        "  Diarrhoea 2/248 (0.81%)",
        "  Vomiting 2/248 (0.81%)"
    ]
}